MARKET

SQZ

SQZ

SQZ Biotechnologies Co
NYSE

Real-time Quotes | Nasdaq Last Sale

12.70
+0.01
+0.08%
After Hours: 12.70 0 0.00% 16:00 04/16 EDT
OPEN
12.89
PREV CLOSE
12.69
HIGH
12.93
LOW
12.31
VOLUME
149.77K
TURNOVER
--
52 WEEK HIGH
36.49
52 WEEK LOW
11.53
MARKET CAP
304.45M
P/E (TTM)
-6.0958
1D
5D
1M
3M
1Y
5Y
SQZ Biotech Presents Preclinical Data on its mRNA-based enhanced APCs and the Potential of the SQZ APC Platform in KRAS Driven Tumors
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today shared preclinical data from its...
BusinessWire - BZX · 04/10 12:30
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 04/09 17:30
The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 30)
Benzinga · 03/31 11:41
Brookline Capital Markets Thinks SQZ Biotechnologies’ Stock is Going to Recover
SmarterAnalyst · 03/30 20:45
The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 29)
Benzinga · 03/30 12:06
Earnings Update: SQZ Biotechnologies Company (NYSE:SQZ) Just Reported And Analysts Are Trimming Their Forecasts
SQZ Biotechnologies Company ( NYSE:SQZ ) came out with its full-year results last week, and we wanted to see how the...
Simply Wall St. · 03/20 09:23
The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 17)
Benzinga · 03/18 12:16
SQZ Biotechnologies EPS misses by $5.90, beats on revenue
SQZ Biotechnologies (SQZ): FY GAAP EPS of -$9.35 misses by $5.90.Revenue of $20.99M (+4.4% Y/Y) beats by $2.93M.Press Release
Seekingalpha · 03/18 11:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SQZ. Analyze the recent business situations of SQZ Biotechnologies Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SQZ stock price target is 37.50 with a high estimate of 40.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 7.25M
% Owned: 30.24%
Shares Outstanding: 23.97M
TypeInstitutionsShares
Increased
0
0
New
35
7.25M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Director
Amy Schulman
Chief Executive Officer/Co-Founder/Director
Armon Sharei
Co-Founder/Director
Klavs Jensen
Chief Financial Officer/Primary Contact
Teri Loxam
Chief Scientific Officer
Howard Bernstein
No Data
About SQZ
SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. It uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in highly immunogenic (HPV) plus tumors. It is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating robust (cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that has been designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.

Webull offers kinds of SQZ Biotechnologies Co stock information, including NYSE:SQZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SQZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SQZ stock methods without spending real money on the virtual paper trading platform.